Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Nasus Pharma Ltd. ( (NSRX) ) is now available.
On January 20, 2026, Nasus Pharma reported positive interim Phase 2 results for NS002, its investigational intranasal epinephrine powder for anaphylaxis, showing faster absorption, higher peak plasma levels, and greater early epinephrine exposure compared with the standard intramuscular EpiPen autoinjector in 50 healthy adults with allergic rhinitis. The interim data indicated that 91% of NS002 recipients reached a key plasma epinephrine threshold within five minutes versus 67% with EpiPen, with NS002 also demonstrating consistent pharmacokinetic advantages under single and repeat dosing, a safety profile marked by mostly mild, self-resolving local adverse events, and pharmacodynamic responses comparable to EpiPen. Nasus Pharma expects to complete the Phase 2 trial by the end of the first quarter of 2026 and is positioning NS002, built on its proprietary Nasax powder-based intranasal platform, as a potential first-in-class needle-free treatment that could enhance patient compliance and strengthen the company’s standing in the anaphylaxis treatment market.
The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company specializing in innovative intranasal powder products for acute and emergency medical conditions in the community setting. Its lead candidate, NS002, is an intranasal powder epinephrine product being developed as a needle-free alternative to epinephrine autoinjectors for treating anaphylaxis, leveraging the company’s proprietary powder-based intranasal technology to enable rapid, reliable drug absorption via the nasal cavity.
Average Trading Volume: 5,275
Technical Sentiment Signal: Strong Sell
For a thorough assessment of NSRX stock, go to TipRanks’ Stock Analysis page.